Zinger Key Points
- Scienture partnered with Kindeva to REZENOPY, an opioid overdose treatment.
- Scienture will own the new drug application and handle sales, marketing and distribution in the U.S.
- Feel unsure about the market’s next move? Copy trade alerts from Matt Maley—a Wall Street veteran who consistently finds profits in volatile markets. Claim your 7-day free trial now.
Scienture Holdings, Inc. SCNX stock is trading higher on Thursday after the company partnered with Kindeva to launch REZENOPY.
What To Know: Under the agreement, Kindeva will manufacture and supply the REZENOPY nasal spray, an opioid overdose treatment. Scienture will own the new drug application and handle sales, marketing and distribution in the U.S.
REZENOPY received approval from the Food and Drug Administration on April 19. It is the highest-strength version of naloxone HCl available on the market.
“This collaboration is not just about expanding our portfolio; it’s about making a real difference in the fight against opioid addiction,” added Shankar Hariharan, Ph.D., CEO of Scienture. “By working alongside public health agencies and community organizations, we will drive meaningful change and save lives.”
See Also: $1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
SCNX Price Action: At the time of writing, Scienture stock is trading 28.7% higher at $2.84, according to data from Benzinga Pro.
Image: via Shutterstock
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
